TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00674193

Intervention type: OTHER
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01323621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
Description: inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 250mcg / salmeterol 50mcg
Description: inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-dummy placebo
Description: inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-dummy placebo
Description: inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol as needed
Description: inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol as needed
Description: inhalation powder
Study: NCT00593801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta
Description: 250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta
Description: 250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
Study: NCT02086851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Motivational Interviewing
Study: NCT01636791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to work
Description: Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return to work
Description: Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
Study: NCT01493258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCOPE Intervention group
Description: The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
Study: NCT01168739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
Study: NCT04628299

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser
Description: Sham Laser in plantar fascia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Induction
Description: Myofascial Induction in plantar fascia
Study: NCT00716053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLVR
Description: BLVR 20 mL

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: BLVR
Description: BLVR 20 mL
Study: NCT01472380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibric acid 105 mg
Description: fenofibric acid 105 mg
Study: NCT04626817

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic device (Biodex System 4)
Description: The measurement of muscle strength with isokinetic device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Isokinetic device (Biodex System 4)
Description: The measurement of muscle strength with isokinetic device
Study: NCT03250832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-033
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
Study: NCT00705432

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b (PEG)
Description: Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG)
Description: Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PEG)
Description: Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
Study: NCT04338828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Gas
Description: Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Supplemental Oxygen
Description: 2 L/min oxygen therapy
Study: NCT00620568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained release tablets taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained release tablets taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained release tablets taken once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained release tablets taken once daily for 14 days
Study: NCT01750541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Study: NCT00892619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using ILM forceps alone
Description: Using ILM forceps to initiate and complete ILM peel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breaking and peeling with end-grasping forceps
Description: Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
Study: NCT05497648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~* One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~* Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions.
Study: NCT02233283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamp
Description: Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamp
Description: Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal
Description: Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal
Description: Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric diet
Description: Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocaloric diet
Description: Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
Study: NCT03653221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard patients with VRNET
Description: In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard patients
Description: In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
Study: NCT01881503

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HBOC-201
Description: HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
Study: NCT03859726

Intervention type: DIAGNOSTIC_TEST
Intervention: NIRS
Description: Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual microcirculation
Description: The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
Study: NCT03427125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: Active control
Study: NCT01288872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
Study: NCT03654313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Part B Placebo
Description: Placebo
Study: NCT00902954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: anastrozole 1 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: anastrozole 1 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: letrozole 2.5 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: letrozole 2.5 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: exemestane 25 mg qd
Study: NCT03565276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A single dose of intravenous TxA in 100ml of 0.9% sodium chloride at 50mg/min, via a dose-escalation design
Study: NCT03909815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual mobility cup
Description: Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cup
Description: Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
Study: NCT03794921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Every Step Counts
Description: Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
Study: NCT04109950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
Study: NCT02612025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
Study: NCT02069353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)
Study: NCT02642510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Education DVD + Verbal Teaching
Description: The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Teaching
Description: Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Teaching
Description: Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
Study: NCT00628303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: 15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
Study: NCT01554488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Propionate
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Fluticasone Propionate
Description: Inhaled corticosteroid
Study: NCT02877927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: po tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: po tablets
Study: NCT01710592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT01771068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple P Positive Parenting Program Discussion Group Dealing with Disobedience
Study: NCT02577601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (LNG)/Ethinyl estradiol birth control pill
Study: NCT00597753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.